Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Respuestas clínicas Cochrane

Topics

Temas

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
Figuras y tablas -
Figure 1

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
Figuras y tablas -
Figure 2

Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.

Ir a la figura de la revisiónAbrir en una pestaña nueva

How does Dihydroartemisinin‐piperaquine perform? Summary of primary outcome: Effectiveness: Total Failure (P. falciparum) PCR adjusted.
Figuras y tablas -
Figure 3

How does Dihydroartemisinin‐piperaquine perform? Summary of primary outcome: Effectiveness: Total Failure (P. falciparum) PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Olliaro‐Vaillant plot. Day 28 PCR adjusted treatment failure data for trials of DHA‐P against all comparators are presented in this plot.The horizontal red line represents the WHO standard of 10% treatment failure (PCR corrected). Plots below this line represent trials where DHA‐P performed to this standard.The vertical blue line represents no difference between the two drugs. Plots to the right of this line represent trials where DHA‐P performed better than the comparator drug, and plots to the left represent trials where the comparator drug performed better than DHA‐P.
Figuras y tablas -
Figure 4

Olliaro‐Vaillant plot. Day 28 PCR adjusted treatment failure data for trials of DHA‐P against all comparators are presented in this plot.

The horizontal red line represents the WHO standard of 10% treatment failure (PCR corrected). Plots below this line represent trials where DHA‐P performed to this standard.

The vertical blue line represents no difference between the two drugs. Plots to the right of this line represent trials where DHA‐P performed better than the comparator drug, and plots to the left represent trials where the comparator drug performed better than DHA‐P.

Ir a la figura de la revisiónAbrir en una pestaña nueva

How does Artesunate plus mefloquine perform? Summary of primary outcome: Effectiveness: Total Failure (P. falciparum) PCR adjusted.
Figuras y tablas -
Figure 5

How does Artesunate plus mefloquine perform? Summary of primary outcome: Effectiveness: Total Failure (P. falciparum) PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Olliaro‐Vaillant plot. Day 28 PCR adjusted treatment failure data for trials of AS+MQ against all comparators are presented in this plot.The horizontal red line represents the WHO standard of 10% treatment failure (PCR corrected). Plots below this line represent trials where AS+MQ performed to this standard.The vertical blue line represents no difference between the two drugs. Plots to the right of this line represent trials where AS+MQ performed better than the comparator drug, and plots to the left represent trials where the comparator drug performed better than AS+MQ.
Figuras y tablas -
Figure 6

Olliaro‐Vaillant plot. Day 28 PCR adjusted treatment failure data for trials of AS+MQ against all comparators are presented in this plot.

The horizontal red line represents the WHO standard of 10% treatment failure (PCR corrected). Plots below this line represent trials where AS+MQ performed to this standard.

The vertical blue line represents no difference between the two drugs. Plots to the right of this line represent trials where AS+MQ performed better than the comparator drug, and plots to the left represent trials where the comparator drug performed better than AS+MQ.

Ir a la figura de la revisiónAbrir en una pestaña nueva

How does Artemether‐lumefantrine perform? Summary of primary outcome: Effectiveness: Total Failure (P. falciparum) Day PCR adjusted.
Figuras y tablas -
Figure 7

How does Artemether‐lumefantrine perform? Summary of primary outcome: Effectiveness: Total Failure (P. falciparum) Day PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Olliaro‐Vaillant plot. Day 28 PCR adjusted treatment failure data for trials of AL6 against all comparators are presented in this plot.The horizontal red line represents the WHO standard of 10% treatment failure (PCR corrected). Plots below this line represent trials where AL6 performed to this standard.The vertical blue line represents no difference between the two drugs. Plots to the right of this line represent trials where AL6 performed better than the comparator drug, and plots to the left represent trials where the comparator drug performed better than AL6.
Figuras y tablas -
Figure 8

Olliaro‐Vaillant plot. Day 28 PCR adjusted treatment failure data for trials of AL6 against all comparators are presented in this plot.

The horizontal red line represents the WHO standard of 10% treatment failure (PCR corrected). Plots below this line represent trials where AL6 performed to this standard.

The vertical blue line represents no difference between the two drugs. Plots to the right of this line represent trials where AL6 performed better than the comparator drug, and plots to the left represent trials where the comparator drug performed better than AL6.

Ir a la figura de la revisiónAbrir en una pestaña nueva

How does Artesunate plus amodiaquine perform? Summary of primary outcome: Effectiveness: Total Failure (P. falciparum) PCR adjusted.
Figuras y tablas -
Figure 9

How does Artesunate plus amodiaquine perform? Summary of primary outcome: Effectiveness: Total Failure (P. falciparum) PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Olliaro‐Vaillant plot. Day 28 PCR adjusted treatment failure data for trials of AS+AQ against all comparators are presented in this plot.The horizontal red line represents the WHO standard of 10% treatment failure (PCR corrected). Plots below this line represent trials where AS+AQ performed to this standard.The vertical blue line represents no difference between the two drugs. Plots to the right of this line represent trials where AS+AQ performed better than the comparator drug, and plots to the left represent trials where the comparator drug performed better than AS+AQ.
Figuras y tablas -
Figure 10

Olliaro‐Vaillant plot. Day 28 PCR adjusted treatment failure data for trials of AS+AQ against all comparators are presented in this plot.

The horizontal red line represents the WHO standard of 10% treatment failure (PCR corrected). Plots below this line represent trials where AS+AQ performed to this standard.

The vertical blue line represents no difference between the two drugs. Plots to the right of this line represent trials where AS+AQ performed better than the comparator drug, and plots to the left represent trials where the comparator drug performed better than AS+AQ.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 1 Total Failure (P. falciparum) Day 63 PCR unadjusted.
Figuras y tablas -
Analysis 1.1

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 1 Total Failure (P. falciparum) Day 63 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 2 Total Failure (P. falciparum) Day 63 PCR adjusted.
Figuras y tablas -
Analysis 1.2

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 2 Total Failure (P. falciparum) Day 63 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 3 Total Failure (P. falciparum) Day 42 PCR unadjusted.
Figuras y tablas -
Analysis 1.3

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 3 Total Failure (P. falciparum) Day 42 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 4 Total Failure (P. falciparum) Day 42 PCR adjusted.
Figuras y tablas -
Analysis 1.4

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 4 Total Failure (P. falciparum) Day 42 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 5 Total Failure (P. falciparum) Day 28 PCR unadjusted.
Figuras y tablas -
Analysis 1.5

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 5 Total Failure (P. falciparum) Day 28 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 6 Total Failure (P. falciparum) Day 28 PCR adjusted.
Figuras y tablas -
Analysis 1.6

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 6 Total Failure (P. falciparum) Day 28 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 7 P. vivax parasitaemia.
Figuras y tablas -
Analysis 1.7

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 7 P. vivax parasitaemia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 8 Gametocyte development (in those negative at baseline).
Figuras y tablas -
Analysis 1.8

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 8 Gametocyte development (in those negative at baseline).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 9 Gametocytaemia carriage.
Figuras y tablas -
Analysis 1.9

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 9 Gametocytaemia carriage.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 10 Serious adverse events (including deaths).
Figuras y tablas -
Analysis 1.10

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 10 Serious adverse events (including deaths).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 11 Early vomiting.
Figuras y tablas -
Analysis 1.11

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 11 Early vomiting.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 12 Sensitivity analysis: Total Failure Day 63 PCR unadjusted.
Figuras y tablas -
Analysis 1.12

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 12 Sensitivity analysis: Total Failure Day 63 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 13 Sensitivity analysis: Total Failure Day 63 PCR adjusted.
Figuras y tablas -
Analysis 1.13

Comparison 1 Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine, Outcome 13 Sensitivity analysis: Total Failure Day 63 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Dihydroartemisinin‐piperaquine vs Artemether‐lumefantrine, Outcome 1 Total Failure (P. falciparum) Day 42 PCR unadjusted.
Figuras y tablas -
Analysis 2.1

Comparison 2 Dihydroartemisinin‐piperaquine vs Artemether‐lumefantrine, Outcome 1 Total Failure (P. falciparum) Day 42 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Dihydroartemisinin‐piperaquine vs Artemether‐lumefantrine, Outcome 2 Total Failure (P. falciparum) Day 42 PCR adjusted.
Figuras y tablas -
Analysis 2.2

Comparison 2 Dihydroartemisinin‐piperaquine vs Artemether‐lumefantrine, Outcome 2 Total Failure (P. falciparum) Day 42 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Dihydroartemisinin‐piperaquine vs Artemether‐lumefantrine, Outcome 3 Total Failure (P. falciparum) Day 28 PCR unadjusted.
Figuras y tablas -
Analysis 2.3

Comparison 2 Dihydroartemisinin‐piperaquine vs Artemether‐lumefantrine, Outcome 3 Total Failure (P. falciparum) Day 28 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Dihydroartemisinin‐piperaquine vs Artemether‐lumefantrine, Outcome 4 Total Failure (P. falciparum) Day 28 PCR adjusted.
Figuras y tablas -
Analysis 2.4

Comparison 2 Dihydroartemisinin‐piperaquine vs Artemether‐lumefantrine, Outcome 4 Total Failure (P. falciparum) Day 28 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Dihydroartemisinin‐piperaquine vs Artemether‐lumefantrine, Outcome 5 P. vivax parasitaemia.
Figuras y tablas -
Analysis 2.5

Comparison 2 Dihydroartemisinin‐piperaquine vs Artemether‐lumefantrine, Outcome 5 P. vivax parasitaemia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Dihydroartemisinin‐piperaquine vs Artemether‐lumefantrine, Outcome 6 Gametocyte development (in those negative at baseline).
Figuras y tablas -
Analysis 2.6

Comparison 2 Dihydroartemisinin‐piperaquine vs Artemether‐lumefantrine, Outcome 6 Gametocyte development (in those negative at baseline).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Dihydroartemisinin‐piperaquine vs Artemether‐lumefantrine, Outcome 7 Anaemia.
Figuras y tablas -
Analysis 2.7

Comparison 2 Dihydroartemisinin‐piperaquine vs Artemether‐lumefantrine, Outcome 7 Anaemia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Dihydroartemisinin‐piperaquine vs Artemether‐lumefantrine, Outcome 8 Serious adverse events (including deaths).
Figuras y tablas -
Analysis 2.8

Comparison 2 Dihydroartemisinin‐piperaquine vs Artemether‐lumefantrine, Outcome 8 Serious adverse events (including deaths).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Dihydroartemisinin‐piperaquine vs Artemether‐lumefantrine, Outcome 9 Early vomiting.
Figuras y tablas -
Analysis 2.9

Comparison 2 Dihydroartemisinin‐piperaquine vs Artemether‐lumefantrine, Outcome 9 Early vomiting.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Dihydroartemisinin‐piperaquine vs Artesunate plus amodiaquine, Outcome 1 Total Failure (P. falciparum) Day 28 PCR unadjusted.
Figuras y tablas -
Analysis 3.1

Comparison 3 Dihydroartemisinin‐piperaquine vs Artesunate plus amodiaquine, Outcome 1 Total Failure (P. falciparum) Day 28 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Dihydroartemisinin‐piperaquine vs Artesunate plus amodiaquine, Outcome 2 Total Failure (P. falciparum) Day 28 PCR adjusted.
Figuras y tablas -
Analysis 3.2

Comparison 3 Dihydroartemisinin‐piperaquine vs Artesunate plus amodiaquine, Outcome 2 Total Failure (P. falciparum) Day 28 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Dihydroartemisinin‐piperaquine vs Artesunate plus amodiaquine, Outcome 3 Total Failure (P. falciparum) Day 42 PCR unadjusted.
Figuras y tablas -
Analysis 3.3

Comparison 3 Dihydroartemisinin‐piperaquine vs Artesunate plus amodiaquine, Outcome 3 Total Failure (P. falciparum) Day 42 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Dihydroartemisinin‐piperaquine vs Artesunate plus amodiaquine, Outcome 4 Total Failure (P. falciparum) Day 42 PCR adjusted.
Figuras y tablas -
Analysis 3.4

Comparison 3 Dihydroartemisinin‐piperaquine vs Artesunate plus amodiaquine, Outcome 4 Total Failure (P. falciparum) Day 42 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Dihydroartemisinin‐piperaquine vs Artesunate plus amodiaquine, Outcome 5 P. vivax parasitaemia.
Figuras y tablas -
Analysis 3.5

Comparison 3 Dihydroartemisinin‐piperaquine vs Artesunate plus amodiaquine, Outcome 5 P. vivax parasitaemia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Dihydroartemisinin‐piperaquine vs Artesunate plus amodiaquine, Outcome 6 Serious adverse events (including deaths).
Figuras y tablas -
Analysis 3.6

Comparison 3 Dihydroartemisinin‐piperaquine vs Artesunate plus amodiaquine, Outcome 6 Serious adverse events (including deaths).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 Dihydroartemisinin‐piperaquine vs Artesunate plus amodiaquine, Outcome 7 Early vomiting.
Figuras y tablas -
Analysis 3.7

Comparison 3 Dihydroartemisinin‐piperaquine vs Artesunate plus amodiaquine, Outcome 7 Early vomiting.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Dihydroartemisinin‐piperaquine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 1 Total Failure (P. falciparum) Day 42 PCR unadjusted.
Figuras y tablas -
Analysis 4.1

Comparison 4 Dihydroartemisinin‐piperaquine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 1 Total Failure (P. falciparum) Day 42 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Dihydroartemisinin‐piperaquine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 2 Total Failure (P. falciparum) Day 42 PCR adjusted.
Figuras y tablas -
Analysis 4.2

Comparison 4 Dihydroartemisinin‐piperaquine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 2 Total Failure (P. falciparum) Day 42 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Dihydroartemisinin‐piperaquine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 3 Total Failure (P. falciparum) Day 28 PCR unadjusted.
Figuras y tablas -
Analysis 4.3

Comparison 4 Dihydroartemisinin‐piperaquine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 3 Total Failure (P. falciparum) Day 28 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Dihydroartemisinin‐piperaquine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 4 Total Failure (P. falciparum) Day 28 PCR adjusted.
Figuras y tablas -
Analysis 4.4

Comparison 4 Dihydroartemisinin‐piperaquine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 4 Total Failure (P. falciparum) Day 28 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 Dihydroartemisinin‐piperaquine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 5 P. vivax parasitaemia by day 42.
Figuras y tablas -
Analysis 4.5

Comparison 4 Dihydroartemisinin‐piperaquine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 5 P. vivax parasitaemia by day 42.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Dihydroartemisinin‐piperaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 1 Total Failure (P. falciparum) Day 28 PCR unadjusted.
Figuras y tablas -
Analysis 5.1

Comparison 5 Dihydroartemisinin‐piperaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 1 Total Failure (P. falciparum) Day 28 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Dihydroartemisinin‐piperaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 2 Total Failure (P. falciparum) Day 28 PCR adjusted.
Figuras y tablas -
Analysis 5.2

Comparison 5 Dihydroartemisinin‐piperaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 2 Total Failure (P. falciparum) Day 28 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Dihydroartemisinin‐piperaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 3 Total Failure (P. falciparum) Day 42 PCR unadjusted.
Figuras y tablas -
Analysis 5.3

Comparison 5 Dihydroartemisinin‐piperaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 3 Total Failure (P. falciparum) Day 42 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Dihydroartemisinin‐piperaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 4 Total Failure (P. falciparum) Day 42 PCR adjusted.
Figuras y tablas -
Analysis 5.4

Comparison 5 Dihydroartemisinin‐piperaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 4 Total Failure (P. falciparum) Day 42 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Dihydroartemisinin‐piperaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 5 Gametocyte development.
Figuras y tablas -
Analysis 5.5

Comparison 5 Dihydroartemisinin‐piperaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 5 Gametocyte development.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Dihydroartemisinin‐piperaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 6 Anaemia.
Figuras y tablas -
Analysis 5.6

Comparison 5 Dihydroartemisinin‐piperaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 6 Anaemia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 Dihydroartemisinin‐piperaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 7 Early vomiting.
Figuras y tablas -
Analysis 5.7

Comparison 5 Dihydroartemisinin‐piperaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 7 Early vomiting.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Artesunate plus mefloquine vs Artemether‐lumefantrine, Outcome 1 Total Failure (P. falciparum) Day 42 PCR unadjusted.
Figuras y tablas -
Analysis 6.1

Comparison 6 Artesunate plus mefloquine vs Artemether‐lumefantrine, Outcome 1 Total Failure (P. falciparum) Day 42 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Artesunate plus mefloquine vs Artemether‐lumefantrine, Outcome 2 Total Failure (P. falciparum) Day 42 PCR adjusted.
Figuras y tablas -
Analysis 6.2

Comparison 6 Artesunate plus mefloquine vs Artemether‐lumefantrine, Outcome 2 Total Failure (P. falciparum) Day 42 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Artesunate plus mefloquine vs Artemether‐lumefantrine, Outcome 3 Total Failure (P. falciparum) Day 28 PCR unadjusted.
Figuras y tablas -
Analysis 6.3

Comparison 6 Artesunate plus mefloquine vs Artemether‐lumefantrine, Outcome 3 Total Failure (P. falciparum) Day 28 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Artesunate plus mefloquine vs Artemether‐lumefantrine, Outcome 4 Total Failure (P. falciparum) Day 28 PCR adjusted.
Figuras y tablas -
Analysis 6.4

Comparison 6 Artesunate plus mefloquine vs Artemether‐lumefantrine, Outcome 4 Total Failure (P. falciparum) Day 28 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Artesunate plus mefloquine vs Artemether‐lumefantrine, Outcome 5 P. vivax parasitaemia.
Figuras y tablas -
Analysis 6.5

Comparison 6 Artesunate plus mefloquine vs Artemether‐lumefantrine, Outcome 5 P. vivax parasitaemia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Artesunate plus mefloquine vs Artemether‐lumefantrine, Outcome 6 Gametocyte development (in those negative at baseline).
Figuras y tablas -
Analysis 6.6

Comparison 6 Artesunate plus mefloquine vs Artemether‐lumefantrine, Outcome 6 Gametocyte development (in those negative at baseline).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Artesunate plus mefloquine vs Artemether‐lumefantrine, Outcome 7 Gametocyte carriage.
Figuras y tablas -
Analysis 6.7

Comparison 6 Artesunate plus mefloquine vs Artemether‐lumefantrine, Outcome 7 Gametocyte carriage.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Artesunate plus mefloquine vs Artemether‐lumefantrine, Outcome 8 Serious adverse events (including deaths).
Figuras y tablas -
Analysis 6.8

Comparison 6 Artesunate plus mefloquine vs Artemether‐lumefantrine, Outcome 8 Serious adverse events (including deaths).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 Artesunate plus mefloquine vs Artemether‐lumefantrine, Outcome 9 Early vomiting.
Figuras y tablas -
Analysis 6.9

Comparison 6 Artesunate plus mefloquine vs Artemether‐lumefantrine, Outcome 9 Early vomiting.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 Artesunate plus mefloquine vs Artesunate plus amodiaquine, Outcome 1 Total Failure (P. falciparum) Day 28 PCR unadjusted.
Figuras y tablas -
Analysis 7.1

Comparison 7 Artesunate plus mefloquine vs Artesunate plus amodiaquine, Outcome 1 Total Failure (P. falciparum) Day 28 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 Artesunate plus mefloquine vs Artesunate plus amodiaquine, Outcome 2 Total Failure (P. falciparum) Day 28 PCR adjusted.
Figuras y tablas -
Analysis 7.2

Comparison 7 Artesunate plus mefloquine vs Artesunate plus amodiaquine, Outcome 2 Total Failure (P. falciparum) Day 28 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 Artesunate plus mefloquine vs Artesunate plus amodiaquine, Outcome 3 Gametocyte carriage.
Figuras y tablas -
Analysis 7.3

Comparison 7 Artesunate plus mefloquine vs Artesunate plus amodiaquine, Outcome 3 Gametocyte carriage.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Artesunate plus mefloquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 1 Total Failure (P. falciparum) Day 28 PCR unadjusted.
Figuras y tablas -
Analysis 8.1

Comparison 8 Artesunate plus mefloquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 1 Total Failure (P. falciparum) Day 28 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Artesunate plus mefloquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 2 Total Failure (P. falciparum) Day 28 PCR adjusted.
Figuras y tablas -
Analysis 8.2

Comparison 8 Artesunate plus mefloquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 2 Total Failure (P. falciparum) Day 28 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 Artesunate plus mefloquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 3 Gametocyte carriage.
Figuras y tablas -
Analysis 8.3

Comparison 8 Artesunate plus mefloquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 3 Gametocyte carriage.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 Artemether‐lumefantrine vs Artesunate plus amodiaquine, Outcome 1 Total Failure (P. falciparum) Day 28 PCR unadjusted.
Figuras y tablas -
Analysis 9.1

Comparison 9 Artemether‐lumefantrine vs Artesunate plus amodiaquine, Outcome 1 Total Failure (P. falciparum) Day 28 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 Artemether‐lumefantrine vs Artesunate plus amodiaquine, Outcome 2 Total Failure (P. falciparum) Day 28 PCR adjusted.
Figuras y tablas -
Analysis 9.2

Comparison 9 Artemether‐lumefantrine vs Artesunate plus amodiaquine, Outcome 2 Total Failure (P. falciparum) Day 28 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 Artemether‐lumefantrine vs Artesunate plus amodiaquine, Outcome 3 Gametocyte development.
Figuras y tablas -
Analysis 9.3

Comparison 9 Artemether‐lumefantrine vs Artesunate plus amodiaquine, Outcome 3 Gametocyte development.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 Artemether‐lumefantrine vs Artesunate plus amodiaquine, Outcome 4 Gametocyte carriage.
Figuras y tablas -
Analysis 9.4

Comparison 9 Artemether‐lumefantrine vs Artesunate plus amodiaquine, Outcome 4 Gametocyte carriage.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 Artemether‐lumefantrine vs Artesunate plus amodiaquine, Outcome 5 Anaemia.
Figuras y tablas -
Analysis 9.5

Comparison 9 Artemether‐lumefantrine vs Artesunate plus amodiaquine, Outcome 5 Anaemia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 Artemether‐lumefantrine vs Artesunate plus amodiaquine, Outcome 6 Proportion anaemic (Haemoglobin < 11 g/dl).
Figuras y tablas -
Analysis 9.6

Comparison 9 Artemether‐lumefantrine vs Artesunate plus amodiaquine, Outcome 6 Proportion anaemic (Haemoglobin < 11 g/dl).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 Artemether‐lumefantrine vs Artesunate plus amodiaquine, Outcome 7 Serious adverse events (including deaths).
Figuras y tablas -
Analysis 9.7

Comparison 9 Artemether‐lumefantrine vs Artesunate plus amodiaquine, Outcome 7 Serious adverse events (including deaths).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 Artemether‐lumefantrine vs Artesunate plus amodiaquine, Outcome 8 Early vomiting.
Figuras y tablas -
Analysis 9.8

Comparison 9 Artemether‐lumefantrine vs Artesunate plus amodiaquine, Outcome 8 Early vomiting.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 Artemether‐lumefantrine vs Artesunate plus amodiaquine, Outcome 9 Sensitivity analysis: Total Failure Day 28 PCR unadjusted.
Figuras y tablas -
Analysis 9.9

Comparison 9 Artemether‐lumefantrine vs Artesunate plus amodiaquine, Outcome 9 Sensitivity analysis: Total Failure Day 28 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 Artemether‐lumefantrine vs Artesunate plus amodiaquine, Outcome 10 Sensitivity analysis: Total Failure Day 28 PCR adjusted.
Figuras y tablas -
Analysis 9.10

Comparison 9 Artemether‐lumefantrine vs Artesunate plus amodiaquine, Outcome 10 Sensitivity analysis: Total Failure Day 28 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 Artemether‐lumefantrine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 1 Total Failure (P. falciparum) Day 42 PCR unadjusted.
Figuras y tablas -
Analysis 10.1

Comparison 10 Artemether‐lumefantrine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 1 Total Failure (P. falciparum) Day 42 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 Artemether‐lumefantrine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 2 Total Failure (P. falciparum) Day 42 PCR adjusted.
Figuras y tablas -
Analysis 10.2

Comparison 10 Artemether‐lumefantrine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 2 Total Failure (P. falciparum) Day 42 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 Artemether‐lumefantrine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 3 Total Failure (P. falciparum) Day 28 PCR unadjusted.
Figuras y tablas -
Analysis 10.3

Comparison 10 Artemether‐lumefantrine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 3 Total Failure (P. falciparum) Day 28 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 Artemether‐lumefantrine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 4 Total Failure (P. falciparum) Day 28 PCR adjusted.
Figuras y tablas -
Analysis 10.4

Comparison 10 Artemether‐lumefantrine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 4 Total Failure (P. falciparum) Day 28 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 Artemether‐lumefantrine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 5 P. vivax parasitaemia.
Figuras y tablas -
Analysis 10.5

Comparison 10 Artemether‐lumefantrine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 5 P. vivax parasitaemia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 Artemether‐lumefantrine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 6 Sensitivity analysis Total Failure Day 28 PCR unadjusted.
Figuras y tablas -
Analysis 10.6

Comparison 10 Artemether‐lumefantrine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 6 Sensitivity analysis Total Failure Day 28 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 Artemether‐lumefantrine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 7 Sensitivity analysis: Total Failure Day 28 PCR adjusted.
Figuras y tablas -
Analysis 10.7

Comparison 10 Artemether‐lumefantrine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 7 Sensitivity analysis: Total Failure Day 28 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 Artemether‐lumefantrine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 1 Total Failure (P. falciparum) Day 28 PCR unadjusted.
Figuras y tablas -
Analysis 11.1

Comparison 11 Artemether‐lumefantrine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 1 Total Failure (P. falciparum) Day 28 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 Artemether‐lumefantrine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 2 Total Failure (P. falciparum) Day 28 PCR adjusted.
Figuras y tablas -
Analysis 11.2

Comparison 11 Artemether‐lumefantrine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 2 Total Failure (P. falciparum) Day 28 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 Artemether‐lumefantrine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 3 Total Failure (P. falciparum) Day 42 PCR unadjusted.
Figuras y tablas -
Analysis 11.3

Comparison 11 Artemether‐lumefantrine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 3 Total Failure (P. falciparum) Day 42 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 Artemether‐lumefantrine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 4 Total Failure (P. falciparum) Day 42 PCR adjusted.
Figuras y tablas -
Analysis 11.4

Comparison 11 Artemether‐lumefantrine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 4 Total Failure (P. falciparum) Day 42 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 Artemether‐lumefantrine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 5 Gametocyte carriage.
Figuras y tablas -
Analysis 11.5

Comparison 11 Artemether‐lumefantrine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 5 Gametocyte carriage.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 Artemether‐lumefantrine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 6 Gametocyte development (in those negative at baseline).
Figuras y tablas -
Analysis 11.6

Comparison 11 Artemether‐lumefantrine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 6 Gametocyte development (in those negative at baseline).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 Artemether‐lumefantrine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 7 Anaemia.
Figuras y tablas -
Analysis 11.7

Comparison 11 Artemether‐lumefantrine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 7 Anaemia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 Artemether‐lumefantrine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 8 Serious adverse events (including deaths).
Figuras y tablas -
Analysis 11.8

Comparison 11 Artemether‐lumefantrine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 8 Serious adverse events (including deaths).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 Artemether‐lumefantrine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 9 Early vomiting.
Figuras y tablas -
Analysis 11.9

Comparison 11 Artemether‐lumefantrine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 9 Early vomiting.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 1 Total Failure (P. falciparum) Day 28 PCR unadjusted.
Figuras y tablas -
Analysis 12.1

Comparison 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 1 Total Failure (P. falciparum) Day 28 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 2 Total Failure (P. falciparum) Day 28 PCR adjusted.
Figuras y tablas -
Analysis 12.2

Comparison 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 2 Total Failure (P. falciparum) Day 28 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 3 Gametocyte carriage.
Figuras y tablas -
Analysis 12.3

Comparison 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 3 Gametocyte carriage.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 4 Proportion of participants with anaemia.
Figuras y tablas -
Analysis 12.4

Comparison 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 4 Proportion of participants with anaemia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 5 Serious adverse events (including deaths).
Figuras y tablas -
Analysis 12.5

Comparison 12 Artesunate plus amodiaquine vs Artesunate plus sulfadoxine‐pyrimethamine, Outcome 5 Serious adverse events (including deaths).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 1 Total Failure (P. falciparum) Day 28 PCR unadjusted.
Figuras y tablas -
Analysis 13.1

Comparison 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 1 Total Failure (P. falciparum) Day 28 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 2 Total Failure (P. falciparum) Day 28 PCR adjusted.
Figuras y tablas -
Analysis 13.2

Comparison 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 2 Total Failure (P. falciparum) Day 28 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 3 Gametocyte development.
Figuras y tablas -
Analysis 13.3

Comparison 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 3 Gametocyte development.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 4 Gametocyte carriage.
Figuras y tablas -
Analysis 13.4

Comparison 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 4 Gametocyte carriage.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 5 Anaemia.
Figuras y tablas -
Analysis 13.5

Comparison 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 5 Anaemia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 6 Serious adverse events (including deaths).
Figuras y tablas -
Analysis 13.6

Comparison 13 Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine, Outcome 6 Serious adverse events (including deaths).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 Dihydroartemisinin‐piperaquine dose analysis: 3 dose vs 4 dose regimen, Outcome 1 Total Failure PCR unadjusted.
Figuras y tablas -
Analysis 14.1

Comparison 14 Dihydroartemisinin‐piperaquine dose analysis: 3 dose vs 4 dose regimen, Outcome 1 Total Failure PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 Dihydroartemisinin‐piperaquine dose analysis: 3 dose vs 4 dose regimen, Outcome 2 Total Failure PCR adjusted.
Figuras y tablas -
Analysis 14.2

Comparison 14 Dihydroartemisinin‐piperaquine dose analysis: 3 dose vs 4 dose regimen, Outcome 2 Total Failure PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 15 Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine), Outcome 1 Total Failure Day 63 PCR unadjusted.
Figuras y tablas -
Analysis 15.1

Comparison 15 Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine), Outcome 1 Total Failure Day 63 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 15 Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine), Outcome 2 Total Failure Day 63 PCR adjusted.
Figuras y tablas -
Analysis 15.2

Comparison 15 Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine), Outcome 2 Total Failure Day 63 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 15 Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine), Outcome 3 Total Failure Day 42 PCR unadjusted.
Figuras y tablas -
Analysis 15.3

Comparison 15 Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine), Outcome 3 Total Failure Day 42 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 15 Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine), Outcome 4 Total Failure Day 42 PCR adjusted.
Figuras y tablas -
Analysis 15.4

Comparison 15 Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine), Outcome 4 Total Failure Day 42 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 15 Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine), Outcome 5 Total Failure Day 28 PCR unadjusted.
Figuras y tablas -
Analysis 15.5

Comparison 15 Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine), Outcome 5 Total Failure Day 28 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 15 Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine), Outcome 6 Total Failure Day 28 PCR adjusted.
Figuras y tablas -
Analysis 15.6

Comparison 15 Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine), Outcome 6 Total Failure Day 28 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 16 Artesunate Mefloquine dose analysis: FDC versus split dose regimen, Outcome 1 Total Failure Day 63 PCR unadjusted.
Figuras y tablas -
Analysis 16.1

Comparison 16 Artesunate Mefloquine dose analysis: FDC versus split dose regimen, Outcome 1 Total Failure Day 63 PCR unadjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 16 Artesunate Mefloquine dose analysis: FDC versus split dose regimen, Outcome 2 Total Failure Day 63 PCR adjusted.
Figuras y tablas -
Analysis 16.2

Comparison 16 Artesunate Mefloquine dose analysis: FDC versus split dose regimen, Outcome 2 Total Failure Day 63 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 17 Artesunate plus mefloquine dose analysis (versus Dihydroartemisinin‐piperaquine), Outcome 1 Total Failure Day 63 PCR adjusted.
Figuras y tablas -
Analysis 17.1

Comparison 17 Artesunate plus mefloquine dose analysis (versus Dihydroartemisinin‐piperaquine), Outcome 1 Total Failure Day 63 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 17 Artesunate plus mefloquine dose analysis (versus Dihydroartemisinin‐piperaquine), Outcome 2 Total Failure Day 28 PCR adjusted.
Figuras y tablas -
Analysis 17.2

Comparison 17 Artesunate plus mefloquine dose analysis (versus Dihydroartemisinin‐piperaquine), Outcome 2 Total Failure Day 28 PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 18 How does Dihydroartemisinin‐piperaquine perform?, Outcome 1 Effectiveness: Total Failure (P. falciparum) PCR adjusted.
Figuras y tablas -
Analysis 18.1

Comparison 18 How does Dihydroartemisinin‐piperaquine perform?, Outcome 1 Effectiveness: Total Failure (P. falciparum) PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 19 How does Artesunate plus mefloquine perform?, Outcome 1 Effectiveness: Total Failure (P. falciparum) PCR adjusted.
Figuras y tablas -
Analysis 19.1

Comparison 19 How does Artesunate plus mefloquine perform?, Outcome 1 Effectiveness: Total Failure (P. falciparum) PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 20 How does Artemether‐lumefantrine perform?, Outcome 1 Effectiveness: Total Failure (P. falciparum) Day PCR adjusted.
Figuras y tablas -
Analysis 20.1

Comparison 20 How does Artemether‐lumefantrine perform?, Outcome 1 Effectiveness: Total Failure (P. falciparum) Day PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 21 How does Artesunate plus amodiaquine perform?, Outcome 1 Effectiveness: Total Failure (P. falciparum) PCR adjusted.
Figuras y tablas -
Analysis 21.1

Comparison 21 How does Artesunate plus amodiaquine perform?, Outcome 1 Effectiveness: Total Failure (P. falciparum) PCR adjusted.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Comparison 1. Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Total Failure (P. falciparum) Day 63 PCR unadjusted Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 Asia

3

1182

Risk Ratio (M‐H, Fixed, 95% CI)

0.73 [0.54, 0.98]

1.2 South America

1

445

Risk Ratio (M‐H, Fixed, 95% CI)

6.19 [1.40, 27.35]

2 Total Failure (P. falciparum) Day 63 PCR adjusted Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 Asia

3

1062

Risk Ratio (M‐H, Fixed, 95% CI)

0.39 [0.19, 0.79]

2.2 South America

1

435

Risk Ratio (M‐H, Fixed, 95% CI)

9.55 [0.52, 176.35]

3 Total Failure (P. falciparum) Day 42 PCR unadjusted Show forest plot

5

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

3.1 Asia

5

1969

Risk Ratio (M‐H, Random, 95% CI)

0.88 [0.46, 1.69]

4 Total Failure (P. falciparum) Day 42 PCR adjusted Show forest plot

5

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 Asia

5

1898

Risk Ratio (M‐H, Fixed, 95% CI)

0.64 [0.30, 1.39]

5 Total Failure (P. falciparum) Day 28 PCR unadjusted Show forest plot

6

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

5.1 Asia

6

2034

Risk Ratio (M‐H, Random, 95% CI)

1.20 [0.22, 6.42]

6 Total Failure (P. falciparum) Day 28 PCR adjusted Show forest plot

6

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

6.1 Asia

6

2020

Risk Ratio (M‐H, Fixed, 95% CI)

0.69 [0.31, 1.56]

7 P. vivax parasitaemia Show forest plot

6

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 Mixed P. falciparum and vivax infection at baseline

5

2248

Risk Ratio (M‐H, Fixed, 95% CI)

0.84 [0.63, 1.12]

7.2 Total P. vivax parasitaemia by day 28

1

402

Risk Ratio (M‐H, Fixed, 95% CI)

7.43 [0.39, 142.89]

7.3 Total P. vivax parasitaemia by day 42

3

1251

Risk Ratio (M‐H, Fixed, 95% CI)

0.79 [0.57, 1.11]

7.4 Total P. vivax parasitaemia by day 63

4

1661

Risk Ratio (M‐H, Fixed, 95% CI)

1.11 [0.91, 1.34]

7.5 P. vivax parasitaemia by day 63 in those negative at baseline

3

1172

Risk Ratio (M‐H, Fixed, 95% CI)

1.22 [0.95, 1.56]

7.6 P. vivax parasitaemia by day 63 in those positive at baseline

2

79

Risk Ratio (M‐H, Fixed, 95% CI)

0.97 [0.57, 1.65]

8 Gametocyte development (in those negative at baseline) Show forest plot

3

1234

Risk Ratio (M‐H, Fixed, 95% CI)

3.06 [1.13, 8.33]

9 Gametocytaemia carriage Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

9.1 Gametocyte carriage day 0

2

1174

Risk Ratio (M‐H, Random, 95% CI)

1.07 [0.66, 1.73]

9.2 Gametocyte carriage day 7

2

1152

Risk Ratio (M‐H, Random, 95% CI)

2.00 [1.54, 2.58]

9.3 Gametocyte carriage day 14

2

1142

Risk Ratio (M‐H, Random, 95% CI)

5.14 [3.17, 8.33]

9.4 Gametocyte carriage day 21

2

1123

Risk Ratio (M‐H, Random, 95% CI)

7.23 [0.10, 519.79]

9.5 Gametocyte carriage day 28

2

1124

Risk Ratio (M‐H, Random, 95% CI)

9.68 [1.23, 75.98]

10 Serious adverse events (including deaths) Show forest plot

7

2374

Risk Ratio (M‐H, Fixed, 95% CI)

0.90 [0.38, 2.15]

11 Early vomiting Show forest plot

7

2473

Risk Ratio (M‐H, Fixed, 95% CI)

0.90 [0.69, 1.16]

12 Sensitivity analysis: Total Failure Day 63 PCR unadjusted Show forest plot

4

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

12.1 Total Failure (P. falciparum) Day 63 PCR unadjusted

4

1627

Risk Ratio (M‐H, Random, 95% CI)

0.94 [0.52, 1.70]

12.2 Total Failure Day 63 PCR unadjusted (losses to follow up included as failures)

4

1801

Risk Ratio (M‐H, Random, 95% CI)

0.95 [0.65, 1.38]

12.3 Total Failure Day 63 PCR unadjusted (losses to follow up included as successes)

4

1801

Risk Ratio (M‐H, Random, 95% CI)

0.94 [0.52, 1.68]

13 Sensitivity analysis: Total Failure Day 63 PCR adjusted Show forest plot

4

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

13.1 Total Failure (P. falciparum) Day 63 PCR adjusted

4

1497

Risk Ratio (M‐H, Random, 95% CI)

0.57 [0.17, 1.83]

13.2 Total Failure Day 63 PCR adjusted (indeterminate PCR included as failures)

4

1508

Risk Ratio (M‐H, Random, 95% CI)

0.67 [0.32, 1.39]

13.3 Total Failure Day 63 PCR adjusted (new infections included as successes)

4

1627

Risk Ratio (M‐H, Random, 95% CI)

0.67 [0.34, 1.35]

13.4 Total Failure Day 63 PCR adjusted (losses to follow up included as failures)

4

1801

Risk Ratio (M‐H, Random, 95% CI)

0.93 [0.67, 1.30]

13.5 Total Failure Day 63 PCR adjusted (losses to follow up included as successes)

4

1801

Risk Ratio (M‐H, Random, 95% CI)

0.67 [0.34, 1.33]
Figuras y tablas -
Comparison 1. Dihydroartemisinin‐piperaquine vs Artesunate plus mefloquine
Ir a la tabla de la revisión
Comparison 2. Dihydroartemisinin‐piperaquine vs Artemether‐lumefantrine

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Total Failure (P. falciparum) Day 42 PCR unadjusted Show forest plot

5

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Africa

3

1136

Risk Ratio (M‐H, Random, 95% CI)

0.44 [0.20, 0.95]

1.2 Asia

1

356

Risk Ratio (M‐H, Random, 95% CI)

0.60 [0.35, 1.05]

1.3 Oceania

1

216

Risk Ratio (M‐H, Random, 95% CI)

1.07 [0.76, 1.50]

2 Total Failure (P. falciparum) Day 42 PCR adjusted Show forest plot

5

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 Africa

3

869

Risk Ratio (M‐H, Fixed, 95% CI)

0.39 [0.24, 0.64]

2.2 Asia

1

317

Risk Ratio (M‐H, Fixed, 95% CI)

0.77 [0.16, 3.76]

2.3 Oceania

1

151

Risk Ratio (M‐H, Fixed, 95% CI)

2.31 [0.85, 6.23]

3 Total Failure (P. falciparum) Day 28 PCR unadjusted Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 Africa

2

484

Risk Ratio (M‐H, Fixed, 95% CI)

0.12 [0.05, 0.32]

3.2 Asia

1

451

Risk Ratio (M‐H, Fixed, 95% CI)

0.43 [0.17, 1.12]

3.3 Oceania

1

224

Risk Ratio (M‐H, Fixed, 95% CI)

1.27 [0.75, 2.15]

4 Total Failure (P. falciparum) Day 28 PCR adjusted Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 Africa

2

453

Risk Ratio (M‐H, Fixed, 95% CI)

0.57 [0.17, 1.99]

4.2 Asia

1

436

Risk Ratio (M‐H, Fixed, 95% CI)

0.90 [0.13, 6.36]

4.3 Oceania

1

193

Risk Ratio (M‐H, Fixed, 95% CI)

3.63 [1.04, 12.60]

5 P. vivax parasitaemia Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 Mixed P. falciparum and vivax infection at baseline

4

1608

Risk Ratio (M‐H, Fixed, 95% CI)

1.02 [0.73, 1.42]

5.2 P. vivax parasitaemia by D28

1

473

Risk Ratio (M‐H, Fixed, 95% CI)

0.05 [0.01, 0.36]

5.3 P. vivax parasitaemia by D42

4

1442

Risk Ratio (M‐H, Fixed, 95% CI)

0.32 [0.24, 0.43]

6 Gametocyte development (in those negative at baseline) Show forest plot

4

1203

Risk Ratio (M‐H, Random, 95% CI)

0.95 [0.35, 2.59]

7 Anaemia Show forest plot

4

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

7.1 Mean haemoglobin (g/dl) at baseline

4

1356

Mean Difference (IV, Fixed, 95% CI)

‐0.07 [‐0.27, 0.13]

7.2 Mean haemoglobin (g/dl) at day 28

1

134

Mean Difference (IV, Fixed, 95% CI)

0.36 [‐0.03, 0.75]

7.3 Mean haemoglobin (g/dl) at day 42

1

375

Mean Difference (IV, Fixed, 95% CI)

0.30 [‐0.02, 0.62]

7.4 Mean change in haemoglobin (g/dl) from baseline to Day 42

2

835

Mean Difference (IV, Fixed, 95% CI)

0.26 [0.00, 0.51]

8 Serious adverse events (including deaths) Show forest plot

5

2110

Risk Ratio (M‐H, Fixed, 95% CI)

1.71 [0.66, 4.46]

9 Early vomiting Show forest plot

2

1147

Risk Ratio (M‐H, Fixed, 95% CI)

1.38 [0.68, 2.78]
Figuras y tablas -
Comparison 2. Dihydroartemisinin‐piperaquine vs Artemether‐lumefantrine
Ir a la tabla de la revisión
Comparison 3. Dihydroartemisinin‐piperaquine vs Artesunate plus amodiaquine

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Total Failure (P. falciparum) Day 28 PCR unadjusted Show forest plot

2

679

Risk Ratio (M‐H, Fixed, 95% CI)

0.53 [0.35, 0.81]

1.1 Africa

1

501

Risk Ratio (M‐H, Fixed, 95% CI)

0.54 [0.34, 0.85]

1.2 Asia

1

178

Risk Ratio (M‐H, Fixed, 95% CI)

0.50 [0.17, 1.42]

2 Total Failure (P. falciparum) Day 28 PCR adjusted Show forest plot

2

629

Risk Ratio (M‐H, Fixed, 95% CI)

0.47 [0.23, 0.94]

2.1 Africa

1

458

Risk Ratio (M‐H, Fixed, 95% CI)

0.59 [0.27, 1.27]

2.2 Asia

1

171

Risk Ratio (M‐H, Fixed, 95% CI)

0.15 [0.02, 1.22]

3 Total Failure (P. falciparum) Day 42 PCR unadjusted Show forest plot

1

152

Risk Ratio (M‐H, Fixed, 95% CI)

0.27 [0.10, 0.72]

3.1 Asia

1

152

Risk Ratio (M‐H, Fixed, 95% CI)

0.27 [0.10, 0.72]

4 Total Failure (P. falciparum) Day 42 PCR adjusted Show forest plot

1

141

Risk Ratio (M‐H, Fixed, 95% CI)

0.10 [0.01, 0.81]

4.1 Asia

1

141

Risk Ratio (M‐H, Fixed, 95% CI)

0.10 [0.01, 0.81]

5 P. vivax parasitaemia Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 Mixed P. falciparum and vivax infection at baseline

1

220

Risk Ratio (M‐H, Fixed, 95% CI)

1.24 [0.67, 2.29]

5.2 P. vivax parasitaemia by day 28

1

181

Risk Ratio (M‐H, Fixed, 95% CI)

0.45 [0.04, 4.90]

5.3 P. vivax parasitaemia by day 42

1

170

Risk Ratio (M‐H, Fixed, 95% CI)

0.25 [0.09, 0.74]

6 Serious adverse events (including deaths) Show forest plot

1

334

Risk Ratio (M‐H, Fixed, 95% CI)

0.14 [0.01, 2.71]

7 Early vomiting Show forest plot

1

334

Risk Ratio (M‐H, Fixed, 95% CI)

0.53 [0.22, 1.30]
Figuras y tablas -
Comparison 3. Dihydroartemisinin‐piperaquine vs Artesunate plus amodiaquine
Ir a la tabla de la revisión
Comparison 4. Dihydroartemisinin‐piperaquine vs Artesunate plus sulfadoxine‐pyrimethamine

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Total Failure (P. falciparum) Day 42 PCR unadjusted Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 Oceania

1

215

Risk Ratio (M‐H, Fixed, 95% CI)

1.03 [0.74, 1.45]

2 Total Failure (P. falciparum) Day 42 PCR adjusted Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 Oceania

1

161

Risk Ratio (M‐H, Fixed, 95% CI)

0.77 [0.39, 1.51]

3 Total Failure (P. falciparum) Day 28 PCR unadjusted Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 Oceania

1

223

Risk Ratio (M‐H, Fixed, 95% CI)

1.01 [0.62, 1.64]

4 Total Failure (P. falciparum) Day 28 PCR adjusted Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 Oceania

1

195

Risk Ratio (M‐H, Fixed, 95% CI)

1.01 [0.46, 2.22]

5 P. vivax parasitaemia by day 42 Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 Participants with P. falciparum mono‐infection at baseline

1

194

Risk Ratio (M‐H, Fixed, 95% CI)

0.45 [0.32, 0.65]

5.2 Participants with P. vivax ± P. falciparum at baseline

1

75

Risk Ratio (M‐H, Fixed, 95% CI)

0.46 [0.27, 0.79]
Figuras y tablas -
Comparison 4. Dihydroartemisinin‐piperaquine vs Artesunate plus sulfadoxine‐pyrimethamine
Ir a la tabla de la revisión
Comparison 5. Dihydroartemisinin‐piperaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Total Failure (P. falciparum) Day 28 PCR unadjusted Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 Africa

2

848

Risk Ratio (M‐H, Fixed, 95% CI)

0.37 [0.25, 0.55]

2 Total Failure (P. falciparum) Day 28 PCR adjusted Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 Africa

2

802

Risk Ratio (M‐H, Fixed, 95% CI)

0.30 [0.17, 0.54]

3 Total Failure (P. falciparum) Day 42 PCR unadjusted Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 Africa

1

341

Risk Ratio (M‐H, Fixed, 95% CI)

0.64 [0.33, 1.24]

4 Total Failure (P. falciparum) Day 42 PCR adjusted Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 Africa

1

319

Risk Ratio (M‐H, Fixed, 95% CI)

0.55 [0.16, 1.83]

5 Gametocyte development Show forest plot

1

367

Risk Ratio (M‐H, Fixed, 95% CI)

0.70 [0.27, 1.79]

6 Anaemia Show forest plot

2

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

6.1 Mean haemoglobin (g/dl) at baseline

1

371

Mean Difference (IV, Fixed, 95% CI)

‐0.20 [‐0.68, 0.28]

6.2 Mean haemoglobin (g/dl) at day 42 or last day of follow up

1

371

Mean Difference (IV, Fixed, 95% CI)

‐0.20 [‐0.51, 0.11]

6.3 Mean packed cell volume at baseline

1

510

Mean Difference (IV, Fixed, 95% CI)

0.0 [‐0.89, 0.89]

6.4 Mean packed cell volume at day 14

1

510

Mean Difference (IV, Fixed, 95% CI)

‐1.10 [‐1.73, ‐0.47]

7 Early vomiting Show forest plot

1

383

Risk Ratio (M‐H, Fixed, 95% CI)

3.34 [0.70, 15.87]
Figuras y tablas -
Comparison 5. Dihydroartemisinin‐piperaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine
Ir a la tabla de la revisión
Comparison 6. Artesunate plus mefloquine vs Artemether‐lumefantrine

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Total Failure (P. falciparum) Day 42 PCR unadjusted Show forest plot

4

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Asia

4

1000

Risk Ratio (M‐H, Random, 95% CI)

0.53 [0.29, 0.94]

2 Total Failure (P. falciparum) Day 42 PCR adjusted Show forest plot

4

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Asia

4

904

Risk Ratio (M‐H, Random, 95% CI)

0.38 [0.05, 2.84]

3 Total Failure (P. falciparum) Day 28 PCR unadjusted Show forest plot

5

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 Africa

2

752

Risk Ratio (M‐H, Fixed, 95% CI)

0.65 [0.48, 0.89]

3.2 Asia

3

854

Risk Ratio (M‐H, Fixed, 95% CI)

0.80 [0.41, 1.58]

4 Total Failure (P. falciparum) Day 28 PCR adjusted Show forest plot

5

1479

Risk Ratio (M‐H, Fixed, 95% CI)

1.25 [0.63, 2.50]

4.1 Africa

2

643

Risk Ratio (M‐H, Fixed, 95% CI)

1.08 [0.41, 2.85]

4.2 Asia

3

836

Risk Ratio (M‐H, Fixed, 95% CI)

1.43 [0.53, 3.86]

5 P. vivax parasitaemia Show forest plot

5

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 Mixed P. falciparum and vivax infection at baseline

5

1279

Risk Ratio (M‐H, Fixed, 95% CI)

1.30 [0.57, 3.00]

5.2 P. vivax parasitaemia by day 28

1

208

Risk Ratio (M‐H, Fixed, 95% CI)

0.22 [0.01, 3.88]

5.3 P. vivax parasitaemia by day 42

4

1003

Risk Ratio (M‐H, Fixed, 95% CI)

0.30 [0.21, 0.41]

6 Gametocyte development (in those negative at baseline) Show forest plot

3

883

Risk Ratio (M‐H, Fixed, 95% CI)

1.33 [0.54, 3.28]

7 Gametocyte carriage Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 Gametocyte carriage day 0

1

294

Risk Ratio (M‐H, Fixed, 95% CI)

0.11 [0.01, 2.10]

7.2 Gametocyte carriage day 3

2

536

Risk Ratio (M‐H, Fixed, 95% CI)

0.56 [0.21, 1.48]

7.3 Gametocyte carriage day 7

3

636

Risk Ratio (M‐H, Fixed, 95% CI)

0.35 [0.14, 0.85]

7.4 Gametocyte carriage day 14

2

536

Risk Ratio (M‐H, Fixed, 95% CI)

0.41 [0.08, 2.10]

8 Serious adverse events (including deaths) Show forest plot

7

1773

Risk Ratio (M‐H, Fixed, 95% CI)

2.96 [0.64, 13.76]

9 Early vomiting Show forest plot

6

1479

Risk Ratio (M‐H, Fixed, 95% CI)

1.07 [0.55, 2.08]
Figuras y tablas -
Comparison 6. Artesunate plus mefloquine vs Artemether‐lumefantrine
Ir a la tabla de la revisión
Comparison 7. Artesunate plus mefloquine vs Artesunate plus amodiaquine

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Total Failure (P. falciparum) Day 28 PCR unadjusted Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 Africa

1

493

Risk Ratio (M‐H, Fixed, 95% CI)

0.54 [0.12, 2.46]

2 Total Failure (P. falciparum) Day 28 PCR adjusted Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 Africa

1

482

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

3 Gametocyte carriage Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 Gametocyte carriage day 0

1

505

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

3.2 Gametocyte carriage day 3

1

505

Risk Ratio (M‐H, Fixed, 95% CI)

17.31 [0.90, 332.99]

3.3 Gametocyte carriage day 7

1

505

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

3.4 Gametocyte carriage day 14

1

505

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]
Figuras y tablas -
Comparison 7. Artesunate plus mefloquine vs Artesunate plus amodiaquine
Ir a la tabla de la revisión
Comparison 8. Artesunate plus mefloquine vs Amodiaquine plus sulfadoxine‐pyrimethamine

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Total Failure (P. falciparum) Day 28 PCR unadjusted Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 Africa

1

300

Risk Ratio (M‐H, Fixed, 95% CI)

1.08 [0.15, 7.59]

2 Total Failure (P. falciparum) Day 28 PCR adjusted Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 Africa

1

296

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

3 Gametocyte carriage Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 Gametocyte carriage day 0

1

306

Risk Ratio (M‐H, Fixed, 95% CI)

0.10 [0.01, 1.81]

3.2 Gametocyte carriage day 3

1

306

Risk Ratio (M‐H, Fixed, 95% CI)

0.21 [0.06, 0.70]

3.3 Gametocyte carriage day 7

1

306

Risk Ratio (M‐H, Fixed, 95% CI)

0.03 [0.00, 0.47]

3.4 Gametocyte carriage day 14

1

306

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]
Figuras y tablas -
Comparison 8. Artesunate plus mefloquine vs Amodiaquine plus sulfadoxine‐pyrimethamine
Ir a la tabla de la revisión
Comparison 9. Artemether‐lumefantrine vs Artesunate plus amodiaquine

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Total Failure (P. falciparum) Day 28 PCR unadjusted Show forest plot

9

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected

1.1 East Africa

3

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

1.2 West Africa

5

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

1.3 South/Central Africa

1

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

2 Total Failure (P. falciparum) Day 28 PCR adjusted Show forest plot

8

1729

Risk Ratio (M‐H, Fixed, 95% CI)

1.65 [0.95, 2.87]

2.1 East Africa

2

365

Risk Ratio (M‐H, Fixed, 95% CI)

0.83 [0.15, 4.59]

2.2 West Africa

5

1245

Risk Ratio (M‐H, Fixed, 95% CI)

1.81 [1.00, 3.26]

2.3 South/Central Africa

1

119

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

3 Gametocyte development Show forest plot

1

305

Risk Ratio (M‐H, Fixed, 95% CI)

0.34 [0.15, 0.74]

4 Gametocyte carriage Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected

4.1 Gametocyte carriage day 0

3

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

4.2 Gametocyte carriage day 3

1

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

4.3 Gametocyte carriage day 7

3

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

4.4 Gametocyte carriage day 14

2

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

5 Anaemia Show forest plot

5

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

5.1 Mean haemoglobin (g/dl) at baseline

4

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.2 Mean haemoglobin (g/dl) at Day 28

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.3 Mean change in haemoglobin (g/dl) from baseline to Day 28

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.4 Mean haematocrit at baseline

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.5 Mean haematocrit at Day 28

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

6 Proportion anaemic (Haemoglobin < 11 g/dl) Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected

6.1 At baseline

1

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.2 At day 28

1

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

7 Serious adverse events (including deaths) Show forest plot

6

2749

Risk Ratio (M‐H, Fixed, 95% CI)

1.11 [0.59, 2.08]

8 Early vomiting Show forest plot

5

1097

Risk Ratio (M‐H, Fixed, 95% CI)

0.87 [0.59, 1.31]

9 Sensitivity analysis: Total Failure Day 28 PCR unadjusted Show forest plot

12

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

9.1 Total Failure (P. falciparum) Day 28 PCR unadjusted

9

3021

Risk Ratio (M‐H, Random, 95% CI)

0.88 [0.60, 1.27]

9.2 Total Failure Day 28 PCR unadjusted (trials with baseline differences included)

12

3719

Risk Ratio (M‐H, Random, 95% CI)

0.69 [0.49, 0.97]

9.3 Total Failure Day 28 PCR unadjusted (losses to follow up included as failures)

9

3230

Risk Ratio (M‐H, Random, 95% CI)

0.81 [0.62, 1.06]

9.4 Total Failure Day 28 PCR unadjusted (losses to follow up included as successes)

9

3230

Risk Ratio (M‐H, Random, 95% CI)

0.89 [0.61, 1.30]

10 Sensitivity analysis: Total Failure Day 28 PCR adjusted Show forest plot

11

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

10.1 Total Failure (P. falciparum) Day 28 PCR adjusted

8

1729

Risk Ratio (M‐H, Fixed, 95% CI)

1.65 [0.95, 2.87]

10.2 Total Failure Day 28 PCR adjusted (trials with baseline differences included)

11

2311

Risk Ratio (M‐H, Fixed, 95% CI)

1.07 [0.69, 1.67]

10.3 Total Failure Day 28 PCR adjusted (indeterminate PCR included as failures)

8

1747

Risk Ratio (M‐H, Fixed, 95% CI)

1.72 [1.06, 2.78]

10.4 Total Failure Day 28 PCR adjusted (new infections included as successes)

8

2064

Risk Ratio (M‐H, Fixed, 95% CI)

1.70 [1.06, 2.75]

10.5 Total Failure Day 28 PCR adjusted (losses to follow up included as failures)

8

2196

Risk Ratio (M‐H, Fixed, 95% CI)

1.01 [0.78, 1.31]

10.6 Total Failure Day 28 PCR adjusted (losses to follow up included as successes)

8

2196

Risk Ratio (M‐H, Fixed, 95% CI)

1.75 [1.08, 2.83]
Figuras y tablas -
Comparison 9. Artemether‐lumefantrine vs Artesunate plus amodiaquine
Ir a la tabla de la revisión
Comparison 10. Artemether‐lumefantrine vs Artesunate plus sulfadoxine‐pyrimethamine

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Total Failure (P. falciparum) Day 42 PCR unadjusted Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 Oceania

1

217

Risk Ratio (M‐H, Fixed, 95% CI)

0.97 [0.68, 1.36]

2 Total Failure (P. falciparum) Day 42 PCR adjusted Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 Oceania

1

158

Risk Ratio (M‐H, Fixed, 95% CI)

0.33 [0.13, 0.86]

3 Total Failure (P. falciparum) Day 28 PCR unadjusted Show forest plot

2

382

Risk Ratio (M‐H, Fixed, 95% CI)

0.74 [0.48, 1.16]

3.1 Africa

1

157

Risk Ratio (M‐H, Fixed, 95% CI)

0.64 [0.28, 1.48]

3.2 Oceania

1

225

Risk Ratio (M‐H, Fixed, 95% CI)

0.79 [0.47, 1.34]

4 Total Failure (P. falciparum) Day 28 PCR adjusted Show forest plot

2

345

Risk Ratio (M‐H, Fixed, 95% CI)

0.53 [0.25, 1.13]

4.1 Africa

1

151

Risk Ratio (M‐H, Fixed, 95% CI)

0.91 [0.34, 2.47]

4.2 Oceania

1

194

Risk Ratio (M‐H, Fixed, 95% CI)

0.28 [0.08, 0.97]

5 P. vivax parasitaemia Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 P. vivax parasitaemia by day 42 (P. vivax ± P. falciparum at baseline)

1

72

Risk Ratio (M‐H, Fixed, 95% CI)

1.05 [0.76, 1.43]

5.2 P. vivax parasitaemia by day 42 (P. falciparum mono‐infection at baseline)

1

196

Risk Ratio (M‐H, Fixed, 95% CI)

1.09 [0.87, 1.35]

6 Sensitivity analysis Total Failure Day 28 PCR unadjusted Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

6.1 Total Failure (P. falciparum) Day 28 PCR unadjusted

2

382

Risk Ratio (M‐H, Fixed, 95% CI)

0.74 [0.48, 1.16]

6.2 Total Failure Day 28 PCR unadjusted (trials with baseline differences included)

4

802

Risk Ratio (M‐H, Fixed, 95% CI)

0.56 [0.39, 0.79]

6.3 Total Failure Day 28 PCR unadjusted (losses to follow up included as failures)

2

409

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.57, 1.17]

6.4 Total Failure Day 28 PCR unadjusted (losses to follow up included as successes)

2

409

Risk Ratio (M‐H, Fixed, 95% CI)

0.74 [0.47, 1.15]

7 Sensitivity analysis: Total Failure Day 28 PCR adjusted Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 Total Failure (P. falciparum) Day 28 PCR adjusted

2

345

Risk Ratio (M‐H, Fixed, 95% CI)

0.53 [0.25, 1.13]

7.2 Total Failure Day 28 PCR adjusted (trials with baseline differences included)

4

718

Risk Ratio (M‐H, Fixed, 95% CI)

0.34 [0.17, 0.66]

7.3 Total Failure Day 28 PCR adjusted (indeterminate PCR included as failures)

2

349

Risk Ratio (M‐H, Fixed, 95% CI)

0.58 [0.29, 1.16]

7.4 Total Failure Day 28 PCR adjusted (new infections included as successes)

2

382

Risk Ratio (M‐H, Fixed, 95% CI)

0.59 [0.29, 1.17]

7.5 Total Failure Day 28 PCR adjusted (losses to follow up included as failures)

2

409

Risk Ratio (M‐H, Fixed, 95% CI)

0.77 [0.48, 1.23]

7.6 Total Failure Day 28 PCR adjusted (losses to follow up included as successes)

2

409

Risk Ratio (M‐H, Fixed, 95% CI)

0.59 [0.30, 1.17]
Figuras y tablas -
Comparison 10. Artemether‐lumefantrine vs Artesunate plus sulfadoxine‐pyrimethamine
Ir a la tabla de la revisión
Comparison 11. Artemether‐lumefantrine vs Amodiaquine plus sulfadoxine‐pyrimethamine

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Total Failure (P. falciparum) Day 28 PCR unadjusted Show forest plot

6

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 East Africa

3

1646

Risk Ratio (M‐H, Fixed, 95% CI)

0.35 [0.30, 0.41]

1.2 West Africa

3

1130

Risk Ratio (M‐H, Fixed, 95% CI)

2.88 [1.86, 4.47]

2 Total Failure (P. falciparum) Day 28 PCR adjusted Show forest plot

5

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 East Africa

2

618

Risk Ratio (M‐H, Fixed, 95% CI)

0.12 [0.06, 0.24]

2.2 West Africa

3

1051

Risk Ratio (M‐H, Fixed, 95% CI)

1.39 [0.55, 3.47]

3 Total Failure (P. falciparum) Day 42 PCR unadjusted Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 West Africa

1

345

Risk Ratio (M‐H, Fixed, 95% CI)

2.64 [1.66, 4.21]

4 Total Failure (P. falciparum) Day 42 PCR adjusted Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 West Africa

1

284

Risk Ratio (M‐H, Fixed, 95% CI)

1.22 [0.44, 3.38]

5 Gametocyte carriage Show forest plot

4

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

5.1 Gametocyte carriage day 0

4

1545

Risk Ratio (M‐H, Fixed, 95% CI)

0.84 [0.51, 1.39]

5.2 Gametocyte carriage day 3

3

1331

Risk Ratio (M‐H, Fixed, 95% CI)

0.43 [0.25, 0.75]

5.3 Gametocyte carriage day 7

4

1538

Risk Ratio (M‐H, Fixed, 95% CI)

0.32 [0.18, 0.54]

5.4 Gametocyte carriage day 14

4

1536

Risk Ratio (M‐H, Fixed, 95% CI)

0.46 [0.21, 1.01]

6 Gametocyte development (in those negative at baseline) Show forest plot

1

371

Risk Ratio (M‐H, Fixed, 95% CI)

0.29 [0.08, 1.04]

7 Anaemia Show forest plot

2

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

7.1 Mean haemoglobin (g/dl) at baseline

2

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

7.2 Mean change in haemoglobin (g/dl) from baseline to Day 28

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

7.3 Mean haemoglobin (g/dl) at Day 42 or last day of follow up.

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

8 Serious adverse events (including deaths) Show forest plot

5

2684

Risk Ratio (M‐H, Fixed, 95% CI)

1.08 [0.56, 2.08]

9 Early vomiting Show forest plot

2

893

Risk Ratio (M‐H, Fixed, 95% CI)

1.42 [0.54, 3.68]
Figuras y tablas -
Comparison 11. Artemether‐lumefantrine vs Amodiaquine plus sulfadoxine‐pyrimethamine
Ir a la tabla de la revisión
Comparison 12. Artesunate plus amodiaquine vs Artesunate plus sulfadoxine‐pyrimethamine

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Total Failure (P. falciparum) Day 28 PCR unadjusted Show forest plot

7

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

1.1 Africa

7

Risk Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

2 Total Failure (P. falciparum) Day 28 PCR adjusted Show forest plot

7

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

2.1 Africa

7

1419

Risk Ratio (M‐H, Fixed, 95% CI)

0.64 [0.37, 1.08]

3 Gametocyte carriage Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

3.1 Gametocyte carriage day 0

3

532

Risk Ratio (M‐H, Random, 95% CI)

0.89 [0.60, 1.32]

3.2 Gametocyte carriage day 3

2

363

Risk Ratio (M‐H, Random, 95% CI)

0.91 [0.67, 1.25]

3.3 Gametocyte carriage day 7

2

363

Risk Ratio (M‐H, Random, 95% CI)

1.02 [0.64, 1.61]

3.4 Gametocyte carriage day 14

3

520

Risk Ratio (M‐H, Random, 95% CI)

1.08 [0.32, 3.73]

4 Proportion of participants with anaemia Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

4.1 At baseline

2

452

Risk Ratio (M‐H, Fixed, 95% CI)

0.91 [0.83, 1.00]

4.2 At Day 28

2

429

Risk Ratio (M‐H, Fixed, 95% CI)

0.95 [0.79, 1.14]

5 Serious adverse events (including deaths) Show forest plot

4

1108

Risk Ratio (M‐H, Fixed, 95% CI)

0.99 [0.14, 7.02]
Figuras y tablas -
Comparison 12. Artesunate plus amodiaquine vs Artesunate plus sulfadoxine‐pyrimethamine
Ir a la tabla de la revisión
Comparison 13. Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Total Failure (P. falciparum) Day 28 PCR unadjusted Show forest plot

8

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 East Africa

5

3317

Risk Ratio (M‐H, Random, 95% CI)

0.72 [0.51, 1.01]

1.2 West Africa

2

766

Risk Ratio (M‐H, Random, 95% CI)

6.57 [0.68, 63.26]

1.3 Other

1

155

Risk Ratio (M‐H, Random, 95% CI)

3.12 [1.05, 9.25]

2 Total Failure (P. falciparum) Day 28 PCR adjusted Show forest plot

6

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 East Africa

3

1515

Risk Ratio (M‐H, Random, 95% CI)

0.44 [0.22, 0.89]

2.2 West Africa

2

701

Risk Ratio (M‐H, Random, 95% CI)

9.72 [1.19, 79.26]

2.3 Other

1

148

Risk Ratio (M‐H, Random, 95% CI)

2.23 [0.58, 8.58]

3 Gametocyte development Show forest plot

2

1354

Risk Ratio (M‐H, Fixed, 95% CI)

0.67 [0.54, 0.82]

4 Gametocyte carriage Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

4.1 Gametocyte carriage day 0

3

909

Risk Ratio (M‐H, Random, 95% CI)

0.69 [0.13, 3.59]

4.2 Gametocyte carriage day 3

1

521

Risk Ratio (M‐H, Random, 95% CI)

0.01 [0.00, 0.23]

4.3 Gametocyte carriage day 7

3

897

Risk Ratio (M‐H, Random, 95% CI)

0.25 [0.02, 2.69]

4.4 Gametocyte carriage day 14

3

894

Risk Ratio (M‐H, Random, 95% CI)

0.57 [0.16, 2.02]

5 Anaemia Show forest plot

4

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

5.1 Mean haemoglobin (g/dl) at baseline

4

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.2 Mean change in haemoglobin (g/dl) from baseline to day 14

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.3 Mean change in haemoglobin (g/dl) from baseline to Day 28

2

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.4 Mean haemoglobin (g/dl) at Day 28

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

6 Serious adverse events (including deaths) Show forest plot

7

4200

Risk Ratio (M‐H, Fixed, 95% CI)

0.61 [0.36, 1.03]
Figuras y tablas -
Comparison 13. Artesunate plus amodiaquine vs Amodiaquine plus sulfadoxine‐pyrimethamine
Ir a la tabla de la revisión
Comparison 14. Dihydroartemisinin‐piperaquine dose analysis: 3 dose vs 4 dose regimen

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Total Failure PCR unadjusted Show forest plot

1

318

Risk Ratio (M‐H, Fixed, 95% CI)

1.72 [0.84, 3.53]

1.1 Day 63

1

318

Risk Ratio (M‐H, Fixed, 95% CI)

1.72 [0.84, 3.53]

2 Total Failure PCR adjusted Show forest plot

1

292

Risk Ratio (M‐H, Fixed, 95% CI)

0.56 [0.05, 6.09]

2.1 Day 63

1

292

Risk Ratio (M‐H, Fixed, 95% CI)

0.56 [0.05, 6.09]
Figuras y tablas -
Comparison 14. Dihydroartemisinin‐piperaquine dose analysis: 3 dose vs 4 dose regimen
Ir a la tabla de la revisión
Comparison 15. Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Total Failure Day 63 PCR unadjusted Show forest plot

4

1784

Risk Ratio (M‐H, Random, 95% CI)

0.83 [0.49, 1.38]

1.1 DHA‐P 4 doses

3

1019

Risk Ratio (M‐H, Random, 95% CI)

0.81 [0.59, 1.10]

1.2 DHA‐P 3 doses

2

765

Risk Ratio (M‐H, Random, 95% CI)

1.44 [0.09, 22.81]

2 Total Failure Day 63 PCR adjusted Show forest plot

4

1634

Risk Ratio (M‐H, Random, 95% CI)

0.48 [0.18, 1.31]

2.1 DHA‐P 4 doses

3

908

Risk Ratio (M‐H, Random, 95% CI)

0.42 [0.17, 1.04]

2.2 DHA‐P 3 doses

2

726

Risk Ratio (M‐H, Random, 95% CI)

1.27 [0.03, 48.28]

3 Total Failure Day 42 PCR unadjusted Show forest plot

5

2126

Risk Ratio (M‐H, Random, 95% CI)

0.77 [0.43, 1.35]

3.1 DHA‐P 4 doses

3

957

Risk Ratio (M‐H, Random, 95% CI)

0.80 [0.50, 1.28]

3.2 DHA‐P 3 doses

3

1169

Risk Ratio (M‐H, Random, 95% CI)

0.88 [0.20, 3.81]

4 Total Failure Day 42 PCR adjusted Show forest plot

5

2043

Risk Ratio (M‐H, Random, 95% CI)

0.62 [0.20, 1.91]

4.1 DHA‐P 4 doses

3

903

Risk Ratio (M‐H, Random, 95% CI)

0.62 [0.14, 2.82]

4.2 DHA‐P 3 doses

3

1140

Risk Ratio (M‐H, Random, 95% CI)

0.70 [0.08, 5.87]

5 Total Failure Day 28 PCR unadjusted Show forest plot

6

2191

Risk Ratio (M‐H, Random, 95% CI)

0.74 [0.20, 2.65]

5.1 DHA‐P 4 doses

4

1075

Risk Ratio (M‐H, Random, 95% CI)

0.56 [0.10, 3.14]

5.2 DHA‐P 3 doses

3

1116

Risk Ratio (M‐H, Random, 95% CI)

1.29 [0.09, 18.93]

6 Total Failure Day 28 PCR adjusted Show forest plot

6

2171

Risk Ratio (M‐H, Random, 95% CI)

0.74 [0.19, 2.86]

6.1 DHA‐P 4 doses

4

1067

Risk Ratio (M‐H, Random, 95% CI)

0.79 [0.10, 6.11]

6.2 DHA‐P 3 doses

3

1104

Risk Ratio (M‐H, Random, 95% CI)

0.79 [0.08, 7.82]
Figuras y tablas -
Comparison 15. Dihydroartemisinin‐piperaquine dose analysis (versus Artesunate plus mefloquine)
Ir a la tabla de la revisión
Comparison 16. Artesunate Mefloquine dose analysis: FDC versus split dose regimen

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Total Failure Day 63 PCR unadjusted Show forest plot

1

423

Risk Ratio (M‐H, Fixed, 95% CI)

0.93 [0.68, 1.27]

2 Total Failure Day 63 PCR adjusted Show forest plot

1

342

Risk Ratio (M‐H, Fixed, 95% CI)

0.66 [0.34, 1.28]
Figuras y tablas -
Comparison 16. Artesunate Mefloquine dose analysis: FDC versus split dose regimen
Ir a la tabla de la revisión
Comparison 17. Artesunate plus mefloquine dose analysis (versus Dihydroartemisinin‐piperaquine)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Total Failure Day 63 PCR adjusted Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Totals not selected

2 Total Failure Day 28 PCR adjusted Show forest plot

2

279

Risk Ratio (M‐H, Fixed, 95% CI)

2.16 [0.23, 19.88]
Figuras y tablas -
Comparison 17. Artesunate plus mefloquine dose analysis (versus Dihydroartemisinin‐piperaquine)
Ir a la tabla de la revisión
Comparison 18. How does Dihydroartemisinin‐piperaquine perform?

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Effectiveness: Total Failure (P. falciparum) PCR adjusted Show forest plot

11

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Day 63: DHA‐P vs Artesunate plus mefloquine

4

1497

Risk Ratio (M‐H, Random, 95% CI)

0.57 [0.17, 1.83]

1.2 Day 42: DHA‐P vs Artemether‐lumefantrine

5

1337

Risk Ratio (M‐H, Random, 95% CI)

0.62 [0.29, 1.30]

1.3 Day 28: DHA‐P vs Artesunate plus amodiaquine

2

629

Risk Ratio (M‐H, Random, 95% CI)

0.42 [0.13, 1.35]

1.4 Day 42: DHA‐P vs Artesunate plus sulfadoxine‐pyrimethamine

1

161

Risk Ratio (M‐H, Random, 95% CI)

0.77 [0.39, 1.51]

1.5 Day 28: DHA‐P vs Amodiaquine plus sulfadoxine‐pyrimethamine

2

802

Risk Ratio (M‐H, Random, 95% CI)

0.32 [0.16, 0.64]
Figuras y tablas -
Comparison 18. How does Dihydroartemisinin‐piperaquine perform?
Ir a la tabla de la revisión
Comparison 19. How does Artesunate plus mefloquine perform?

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Effectiveness: Total Failure (P. falciparum) PCR adjusted Show forest plot

9

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Day 63: AS+MQ vs Dihydroartemisinin‐piperaquine

4

1497

Risk Ratio (M‐H, Random, 95% CI)

1.77 [0.55, 5.72]

1.2 Day 42: AS+MQ vs Artemether‐lumefantrine

4

904

Risk Ratio (M‐H, Random, 95% CI)

0.38 [0.05, 2.84]

1.3 Day 28: AS+MQ vs Artesunate plus amodiaquine

1

482

Risk Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

1.4 Day 28: AS+MQ vs Artesunate plus sulfadoxine‐pyrimethamine

0

0

Risk Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

1.5 Day 28: AS+MQ vs Amodiaquine plus sulfadoxine‐pyrimethamine

1

296

Risk Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]
Figuras y tablas -
Comparison 19. How does Artesunate plus mefloquine perform?
Ir a la tabla de la revisión
Comparison 20. How does Artemether‐lumefantrine perform?

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Effectiveness: Total Failure (P. falciparum) Day PCR adjusted Show forest plot

19

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Day 42: AL vs Dihydroartemisinin‐piperaquine

5

1337

Risk Ratio (M‐H, Random, 95% CI)

1.61 [0.77, 3.39]

1.2 Day 42: AL vs Artesunate plus mefloquine

4

904

Risk Ratio (M‐H, Random, 95% CI)

2.66 [0.35, 20.09]

1.3 Day 28: AL vs Artesunate plus amodiaquine

8

1729

Risk Ratio (M‐H, Random, 95% CI)

1.71 [0.97, 3.02]

1.4 Day 42: AL vs Artesunate plus sulfadoxine‐pyrimethamine

1

158

Risk Ratio (M‐H, Random, 95% CI)

0.33 [0.13, 0.86]

1.5 Day 28: AL vs Amodiaquine plus sulfadoxine‐pyrimethamine

5

1669

Risk Ratio (M‐H, Random, 95% CI)

0.40 [0.08, 2.11]
Figuras y tablas -
Comparison 20. How does Artemether‐lumefantrine perform?
Ir a la tabla de la revisión
Comparison 21. How does Artesunate plus amodiaquine perform?

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Effectiveness: Total Failure (P. falciparum) PCR adjusted Show forest plot

19

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Day 28: AS+AQ vs Dihydroartemisinin‐piperaquine

2

629

Risk Ratio (M‐H, Random, 95% CI)

2.36 [0.74, 7.54]

1.2 Day 28: AS+AQ vs Artesunate plus mefloquine

1

482

Risk Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

1.3 Day 28: AS+AQ vs Artemether‐lumefantrine

8

1729

Risk Ratio (M‐H, Random, 95% CI)

0.59 [0.33, 1.03]

1.4 Day 28: AS+AQ vs Artesunate plus sulfadoxine‐pyrimethamine

7

1419

Risk Ratio (M‐H, Random, 95% CI)

0.70 [0.34, 1.45]

1.5 Day 28: AS+AQ vs Amodiaquine plus sulfadoxine‐pyrimethamine

6

2364

Risk Ratio (M‐H, Random, 95% CI)

0.74 [0.33, 1.63]
Figuras y tablas -
Comparison 21. How does Artesunate plus amodiaquine perform?
Ir a la tabla de la revisión